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ABSTRACT
Introduction: Indications and techniques of lymph node dissection (LND) for upper tract urothelial
carcinoma (UTUC) are still controversial.
Areas covered: In this study, a systematic review of the English-language literature was performed up
to 1 July 2016 using the Medline, Scopus, Cochrane Library and Web of Sciences databases to provide a
detailed overview of the most commonly dissected surgical templates of LND for UTUC according to
laterality and location of the tumor. Overall, sixteen studies were analyzed. Based on the shared
experiences in the scientific literature, the LND template typically included: for right-sided tumors of
the renal pelvis, upper third and middle third of the ureter, the renal hilar, paracaval, precaval and
retrocaval nodes, while for left-sided tumors the renal hilar, paraaortic and preaortic nodes. For tumors
of the lower ureter, an extended pelvic LND was performed in most cases; however, the paracaval,
paraaortic or presacral nodes were dissected in selected series.
Expert commentary: LND is not routinely performed at the time of surgery for UTUC and both
indication and extent of LND vary among surgeons and institutions. Future high-quality studies are
needed to define the most accurate LND templates and to assess their oncological efficacy and
surgical morbidity.
ARTICLE HISTORY
Received 25 October 2016
Accepted 18 January 2017
KEYWORDS
Anatomic landmarks;
lymphadenectomy; lymph
node dissection; template;
transitional cell carcinoma;
upper tract urothelial
carcinoma; UTUC
1. Introduction
Regional lymph nodes (LNs) represent the most common meta-
static site of upper tract urothelial carcinoma (UTUC). As such,
LN metastases represent a critical prognostic factor [1]. LN
dissection (LND) has shown to achieve accurate staging [2–4],
increased patient survival [2,5–10], possible treatment of micro-
metastases [8,11,12] and less in-field recurrence [13].
Nonetheless, indications, techniques and outcomes of LND for
UTUC are still debated in the current literature [6–8], and its
therapeutic benefit remains controversial [4,7,14–17].
A proper LND is not routinely performed at the time of radical
nephroureterectomy (RNU), even at high-volume centers [4,18].
Key issues to explain this lack of consensus are inadequate
preoperative disease staging, lack of risk-adjusted strategies to
select patients eligible for LND, and the inherent variability of
lymphatic drainage from UTUC [14]. Moreover, there is lack of
standardization in the critical steps of LND and in the reporting of
LND results among surgeons/Institutions, which is potentially
driven by the lack of specific suggestions by the current
Guidelines [19]. On this regard, due to the paucity of available
evidence, it is almost unknown whether the lack of standardiza-
tion involves also the anatomical landmarks of dissection [20,21].
Therefore, the aim of this review is to provide a detailed
summary of the available studies in literature that provided
specific information on the anatomical landmarks and surgical
templates of LND for UTUC, according to laterality and loca-
tion of the primary tumor.
2. Materials and methods
2.1. Search strategy
A systematic review of the English-language literature was
performed according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) criteria
[22]. The Medline, Scopus, Cochrane Library and Web of
Sciences databases were screened without time limit up to
1 July 2016 using the keywords ‘lymph node dissection’ or
‘lymphadenectomy’ or ‘lymph nodes’ or ‘lymphatic drainage’
AND ‘template’ or ‘landmarks’ or ‘mapping’ and ‘upper tract
urothelial carcinoma’ or ‘UTUC’ (Search Query: ((lymph node
dissection) or (lymphadenect*) or (lymph node*) or (lymphatic
drainage) or landmarks or template or mapping)) and ((upper
tract) and ((urothelial carcinoma) or (UTUC) or (transitional
cell carcinoma))). In addition, the reference list of each
selected original articles and previous review articles about
this topic were used to screen for further eligible articles.
Two reviewers (R.C. and A.M.) carried out this process inde-
pendently. The list of articles that were judged highly
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relevant by these authors was reviewed by all co-authors
until a final consensus based on a majoritarian system was
reached for the articles to be included.
2.2. Study selection
All selected studies were screened to retrieve information on the
surgical template of LND, the laterality and the location of the
primary tumor as well as the number of LNs removed and of LN
metastases (LNM) in each site of the template. All the studies that
described the execution of surgical treatment of UTUC without
LND dissection were excluded. Moreover, those studies with the
lack of information on the anatomical boundaries of LND were
also excluded.
2.3. Data extraction
A data extraction form was developed a priori in order to
collect relevant information on study design and level of
evidence, number of the patients included, the selection cri-
teria for LND, standardized definition of LND templates, and
LND metrics (number of LNs removed). Moreover, relevant
information on the number of LNMs, number of LNs dissected
in each anatomical site of the template), UTUC characteristics
(laterality and location in the upper urinary tract), and surgical
approach were collected (Table 1).
A specific electronic extraction sheet was used to collect
detailed information regarding the anatomical landmarks of
LND according to laterality (right vs. left-sided) and location
(renal pelvis (RP), and upper, middle, and lower third of the
ureter) of the index UTUC (Table 2). In this regard, upper,
middle, and lower ureter were defined as ‘superior to the
inferior mesenteric artery (IMA)’, ‘from the level of IMA to the
crossing of common iliac artery’ and ‘below the crossing of
common iliac artery’ respectively [14].
3. Results
In total, 702 articles were preliminarily identified. After exclusion
of duplicates generated by the re-execution of the research
query inmultiple databases (n = 365) and the exclusion of papers
without specific information on LND templates and/or outcomes
(n = 270), 76 papers were selected. A second screening phase
was performed for these studies, which identified overlapping
surgical series (n = 5), previous reviews of this topic (n = 13) and
studies that did not fulfill the predefined quality criteria (n = 33).
In total, 16 studies recruiting 1705 patients fulfill all the inclusion
criteria and were selected for this review (Figure 1).
3.1. Type of studies and quality of reporting LND results
The information provided in each study, including quality assess-
ment measures, are listed in Table 1. Out of 16 studies that met
the inclusion criteria for this review, 14 were retrospective cohort
studies, of which nine single center and fivemulticenter, and two
were prospective cohort studies (1 single- and 1 multicenter).
Only two studies were specifically designed to determine the
primary patterns of lymphatic spread from UTUC and the inci-
dence of LNMs in each anatomical site of the template (mapping
studies) [23–25]. Sample size, tumor location, and stage were
inhomogeneous throughout the studies. All studies described an
open surgical approach for both RNU and LND. A minimally
invasive approach was used in some series, using either a laparo-
scopic (n = 7) and/or robotic approach (n = 2).
In almost all studies, the author did not define a priori specific
selection criteria for LND, being the choice to perform LND left to
the surgeons’ judgment and/or based onpreoperative/intraopera-
tive suspicion of LNMs. Moreover, in most studies the extent of
LND was not standardized. In particular, some studies described a
standard template of dissection according to either laterality [26–
28] or location [7,8,23,29] of the primary tumor. Only a few series
used a standardized template according to both, tumor laterality
and location [10,12,24,25]. The overall number of LNs removed in
each study is shown in Supplementary Figure 1; however, due to
the lack of standardized templates of LND, the number of LNs
dissected and LNMs in each anatomical site were rarely reported
in the published series.
3.2. Templates of LND for UTUC of the RP and upper/
middle third of the ureter
For tumors of the right renal pelvis (RP), upper ureter (UU), and
middle ureter (MU), the LND template included in themajority of
the studies the renal hilar, precaval, and paracaval nodes
[3,7,8,10,12,23–25,27,29–31], extending the dissection to the
posterior aspect of the inferior vena cava by transection of the
lumbar veins, similar to retroperitoneal LN dissection for testicu-
lar tumors [27], in order to dissect the retrocaval nodes (Figure 2).
For left-sided tumors, the LND template included in most cases
the renal hilar, pre- and paraaortic nodes [3,7,8,12,23–25,27,29–
31] (Figure 3, Table 2). Discrepancies were found among the
selected series on some specific anatomical sites included in
the template and on the lower boundary of LND, such as the
dissection of interaortocaval nodes, lower boundary of dissection
(IMA vs. AB) and the dissection of the pelvic iliac nodes (especially
for MU-UTUCs) (Figure 2). For RP-UTUC, the removal of interaor-
tocaval nodes was considered not commonly accepted among
the studies, especially for left-sided tumors [10,12,25,27,28,31].
Matin et al. showed the apparent secondary involvement of
interaortocaval nodes suggesting the possible role of intraopera-
tive frozen section analysis to omit dissection of these nodes in
the case of negative paracaval/retrocaval (for the right side) or
paraaortic (left side) areas [25]. In contrast, a significant propor-
tion of LNMs was found in the interaortocaval region in case of
MU-UTUCs [25]. Moreover, the same authors outlined the con-
stant presence of out-of-field positive LNs (such as suprahilar,
common iliac, aortic bifurcation, and others (Table 2) [25] in case
of primary LNMs in the hilar or paravascular areas.
For RP and UU-UTUC, most studies proposed the level of IMA
as the lower boundary of dissection [7–9,29,30]. However, some
authors extended the dissection along the great vessels until the
level of AB [12,23,24] or of the vena cava bifurcation (for right-
sided tumors only, [25]). For MU-UTUCs, a high variability was
found regarding the lower limit of LND proposed by different
authors. Most studies extended the dissection beyond the AB to
include also the common [3,7–9,23,25,29,30,32] and external
[25], or internal [32] iliac nodes. In one study, the dissection
template included only the ipsilateral pelvic LNs [27].
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3.3. LND template for UTUC of the lower third of ureter
In most studies, the LND template for tumors of the lower third
of ureter included only the ipsilateral pelvic LNs (common,
external, internal iliac and obturator nodes) (Figure 3, Table 2).
Of note, Matin et al. reported the upward migration of metas-
tases to the paracaval and paraaortic regions from mid and
distal ureteral tumors [25]. As such, some studies included the
paracaval (for right-sided tumors) [25], paraaortic (for left-sided
tumors) [23,25,32], or presacral nodes [10] in the template.
4. Discussion
4.1. Rationale for LND at the time of RNU for UTUC
Urothelial carcinoma of the bladder and of upper urinary tract
represent two distinct diseases in terms of anatomical, biolo-
gical and molecular features [33]. While the prognostic role of
LND at radical cystectomy is significantly supported by the
evidence and the anatomical templates have been extensively
evaluated [34,35], on the contrary LND at the time of RNU has
not gained the same oncological role.
In this regard, many studies evaluating the impact of LND for
bladder cancer outlined that extended pelvic lymphadenectomy
can be curative in patients with metastasis or micro-metastasis
to a few nodes and that there is a need for standardization of
LND templates during RC in order to improve surgical quality
and BC patient survival [36,37]. The same conclusions were
reached by Bruins et al that outlined the oncologic advantages
of performing an extended versus limited LND [38]. Most impor-
tantly, a recent paper elegantly showed that, as long as the
surgeon adheres to a standardized LND template, the LN count
does not affect long-term survival after RC [39]. Therefore, as
claimed by many authors [31,39,40], LN count might be inaccu-
rate to define a proper LND, being a better surrogate of the
quality of dissection, rather than its extent [41]. As such, only a
meticulous dissection within well-defined anatomical bound-
aries can ensure completeness of LND to optimize the oncolo-
gical outcomes.
All these findings from the literature on BC provide the
rationale to evaluate whether the anatomical extent of LND
does provide an oncological benefit for UTUC.
However, due to the variable lymphatic drainage from
UTUC and the lack of well established guidelines recom-
mendations [14], it is still debated within the urological
community whether LND may provide an oncological ben-
efit compared to RNU alone [19] and, although a growing
body of evidence has evaluated the staging and therapeu-
tic benefit of LND for UTUC, there is currently lack of
knowledge on its specific anatomical boundaries and selec-
tion criteria.
Records identified through Medline, Web of Science 
and Scopus databases  
Search Query: ((lymph node dissection) OR 
(lymphadenectomy) OR (lymph node*) OR (lymphatic 
drainage) OR landmarks OR template OR mapping) AND 
((upper tract) AND ((urothelial carcinoma) OR (UTUC) OR 
(transitional cell carcinoma))) 
Limits: English-language articles
(n = 679) 
S
c
r
e
e
n
in
g
 
In
c
lu
d
e
d
 
E
li
g
ib
il
it
y
 
Id
e
n
t
if
ic
a
t
io
n
 
Additional records identified from reference 
lists of original articles and review articles 
and from further up-to-date literature search
(n = 23) 
Records screened after  
duplicates removed
(n =  337)
Records excluded after title and abstract review (n = 261) 
- Not relevant to the topics of the review (n = 207) 
-  Meeting abstracts, case reports, editorials (n = 54)
Full-text articles assessed  
for eligibility
(n = 76 )
Articles excluded after full-text evaluation (n= 60) 
- Overlapping surgical series (n= 5) 
- Previous reviews on the topic (n= 13) 
- Lack of detailed description of anatomical 
templates of LND (n= 9 ) 
- Insufficient relevance for the topics of this 
review (n= 33 ) 
Studies included in the 
analysis for this review 
(n = 16 )
Figure 1. Literature search and study selection process according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement
criteria.
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Overall, according to the available evidence, it is still unti-
mely to address whether performing LND for UTUC does
provide a clinically significant benefit for ultimate oncologic
outcomes of UTUC patients. As such, in the attempt to define
the background for future high-quality prospective studies
addressing the potential role of lymphadenectomy for UTUC
outcomes, we provided a detailed overview of the currently
available evidence on anatomical landmarks and surgical tem-
plates of LND for UTUC.
4.2. Selection criteria for LND
To date, the current Guidelines provided by European
Association of Urology (EAU) recommend LND for all invasive
UTUCs, without specifying both selection criteria and extent of
dissection [14]. In this regard, defining specific selection cri-
teria for extended LND is a primary clinical need as the careful
balance between oncological benefits and potential surgical
harms of LND is crucial for patient counseling.
In our analysis most studies did not use or report informa-
tion on the clinical criteria that lead the surgeon to perform
LND. In particular, in the studies by Komatsu [23] and Batata
[32], despite the authors aimed to assess the survival benefit
of LND, no information were reported on the selection criteria
for LND. Similarly, Akaza et al and Busby et al. [27,42] did not
report any information on the clinical characteristics of UTUC
that lead the surgeon to perform LND, although they men-
tioned whether LND was performed. Contrarily, in the pro-
spective study by Rao et al. [28] that aimed to assess the
feasibility of a new technique of retroperitoneal LND for
UTUC, it was not reported in the manuscript the potentials
reasons for not performing LND. Finally, in the retrospective
mapping study conducted by Matin et al., to investigate the
patterns of lymphatic spread from UTUC, the authors clearly
defined the absence of any information about LND selection
criteria as a critical limitation of the study [25].
More importantly, a great inhomogeneity was found also
among the eight studies that proposed standardized selection
criteria for LND. In one study, the eligibility for LND was decided
Figure 2. Schematic view of critical anatomical landmarks (left side) and templates (right side) of lymph node dissection for upper tract urothelial carcinoma.
A: aorta; IVC: inferior vena cava; GV: gonadal vein; GA: gonadal artery; AB: aortic bifurcation; VCB: vena cava bifurcation; CIA: common iliac artery; EIA: external iliac
artery; IIA: internal iliac artery; CIAB: common iliac artery bifurcation; RH: renal hilum; SMI: superior mesenteric artery; IMA: inferior mesenteric artery; Ki: kidney;
Ad: adrenal; UB: urinary bladder.
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by the treating surgeon during RNU in the absence of any pre-
operative clinical evaluation [26]. In other studies, the eligibility
for LND was based on both the pre-operative (i.e. enlarged LN at
the MRI) and intra-operative suspicion of LN metastasis during
the surgical procedure (i.e. presence of infiltrative disease or
enlarged nodes) and the presence of severe patient comorbid-
ities [3,7,8,10,11,24,30]. Finally, in the study conducted by Abe
et al., the eligibility for LND was determined by the absence at
the preoperative time of apparent LN swelling, severe hydrone-
phrosis, or perirenal/periureteral invasion [11]. It is important to
highlight that in the high volume centers performing routinely
LND for UTUC, there was a trend toward a more standardized
definition of the selection criteria for LND overtime [10,24,31].
4.3. Surgical boundaries of LND according to laterality
and location
Our review has shown that the anatomical templates of dissec-
tion for UTUC of the renal pelvis (RP), upper ureter (UU) and
middle ureter (MU) included in most cases the nodes along the
great vessel from the renal hilum to the aortic bifurcation, while
for UTUC of the lower ureter an extended pelvic (Figure 3).
However, these findings have been obtained by a qualitative
analysis of the description of the LND template provided by
each study included in our review. To this regard, the lack of a
standardized template of LND according to laterality and/or
location (or both) of the primary UTUC in most studies
[3,7,8,23,26–30,32,42] may hinder the comparison of the avail-
able surgical series and the interpretation of their results.
Moreover, only in few series the specific number of LNs
removed an LNM in each site of the template were accurately
reported [10,24–26]. This lack of uniform reporting, together
with the lack of standardized anatomical boundaries of LND,
may lead to a potentially inaccurate estimation of the specific
sites of lymphatic drainage for each anatomical location of
UTUC. With regard the surgical approach for RNU and LND, it
must be noted that our review was focused on the anatomical
templates of lymphadenectomy independently from the surgi-
cal approach used. For that reason, our analysis does not
provide a truthful overview of the surgical approaches used to
perform LND. It was not possible to discuss the feasibility of
minimal-invasive approaches for LND in terms of complications
Figure 3. Schematic view of the most commonly dissected templates of lymph node dissection for upper tract urothelial carcinoma of the renal pelvis, upper third,
middle third and lower third of the ureter according to laterality of the tumour based on the studies included in our review. The ongoing controversies regarding
the anatomical boundaries of dissection are also outlined.
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rate and completeness of dissection since it was not the pri-
mary aim of this review. Moreover, it was not possible to assess
the complications rate of each anatomical template of LND as
the reporting of surgical morbidity of LND was either lacking or
unstandardized in most studies included in the review.
However, we believe that the relationships between surgical
approach (open, laparoscopic, robotic), anatomical template of
LND and extent of surgical morbidity is of utmost importance
and should be accurately addressed in future prospective stu-
dies using a standardized template of dissection.
4.4. Limitations at a study- and review-level
This is the first systematic review of the literature specifically
designed to provide detailed data on the most commonly
dissected surgical templates of LND for UTUC according to
both laterality and location of the tumour with the aim to
define the current state of the art and the most relevant
research needs and future perspectives. However, it does
have limitations at both a study- and review-level.
First, many studies analyzed by our review showed several
limitations and great inhomogeneity with regard to study
design, quality of reporting and standardization of LND
templates.
The exclusion of studies addressing the role of LND for
UTUC that did not report a detailed description of the anato-
mical templates of LND may have resulted in selection bias,
potentially reducing the generalization of our conclusions.
Secondly, even among the finally included in the review, the
lack of uniformity in reporting LND templates and the specific
site of LNMs may have hindered the understanding of patterns
of lymphatic drainage from UTUC (in most studies it was
reported only the specific sites of LND and not whether
LNMs were present in those areas).
Regarding the limitations of the study design, only two
studies included in our analysis were prospective and sample
size, tumor location and tumor stage were inhomogeneous
throughout the studies. These limitations may prevent an
accurate interpretation on available evidence from both a
methodological and clinical point of view.
As previously discussed, in almost all studies there were no
standardized criteria for LND, being the choice of performing
LND left at the surgeons’ judgment. Moreover, the extent of
LND was not standardized in most series and the exact num-
ber of LNs dissected and LNMs in each anatomical site of the
template was not reported. Finally, most studies did not spe-
cify in a standardized way the exact tumor location and later-
ality in relation to the LND templates.
4.5. Future perspectives and research need
Prospective high-quality studies are required to provide
insights on the therapeutic efficacy of LND for UTUC. Thus,
standardization in both LND templates and reporting of surgi-
cal results is warranted. As such, we believe a more thoughtful
reporting of the templates of dissection used and the exten-
sion of LND performed will be key to share valuable informa-
tion between surgeons/Institutions. It should be mentioned
that the surgical approach (open, laparoscopic, robot-assisted)
should not matter as long as oncological principles and dis-
section templates are being respected. The overall number of
LNs removed, the specific number of LNs dissected and of
LNMs in each anatomical site of the template should be
reported. The anatomical template should guide the dissec-
tion, while the number of LNs removed might provide a
summary measure of the dissection quality [6]. Moreover,
accurate reporting of tumor location, laterality and staging
(both, clinical and pathological TNM classification) should be
provided in future series. Finally, a detailed description of the
complication rates associated with each dissection template
and type of surgical approach using standardized instruments
should be added. This aspect will be key to evaluate indica-
tions, oncological benefits and potential comorbidities of each
dissection template in a meaningful way.
5. Expert commentary
The aim of our review was to collect all the available evidence
on the anatomical landmarks and the surgical templates of
LND for UTUC according to laterality and location of the tumor
as well as the selection criteria for LND.
Based on the shared experiences in the scientific literature,
the LND template for UTUC of the upper/middle ureter and
renal pelvis typically included the renal hilar, paracaval, pre-
caval, retrocaval nodes and the renal hilar, paraaortic and
preaortic nodes for right-sided and left-sided tumors, respec-
tively. For tumors of the lower ureter, an extended pelvic LND
involving the common, external, internal iliac and obturatory
nodes was performed in most series.
However, LND is not routinely performed at the time of
surgery, and in most series both, indication and extent of LND
vary among surgeons and institutions.
Future high-quality studies are needed to define the most
accurate LND templates and to assess their oncological effi-
cacy and surgical morbidity.
6. Five-year view
The current role of lymph node dissection (LND) for ultimate
oncologic outcomes of patients with UTUC is still controver-
sial. Consequently, there are currently no objective selection
criteria for LND and both surgical techniques and anatomical
templates are not standardized among surgeons and
Institutions worldwide.
In this complex clinical scenario, future clinical research will
have to address two distinct unmet clinical needs. Prospective,
well-designed clinical trials will be indeed key to: 1) fill the
current gaps of knowledge on the anatomical sites of lympha-
tic spread from UTUC and 2) understand whether LND does
provide a (cancer-specific) survival advantage in patients with
UTUC and, if so, define the proper extent of dissection for each
tumor location within the upper urinary tract in order to
balance oncologic efficacy and surgical morbidity. To reach
these goals, the study design will be of paramount importance.
Indeed, such trials should (a) use standardized surgical tem-
plates with clearly defined anatomical boundaries to have the
possibility to perform mapping studies; (b) be able to compare
oncologic efficacy and surgical morbidity of different surgical
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approaches (open vs. laparoscopic vs. robotic) by using the
same templates among different surgeons/institutions; (c) take
into account the increasing role of kidney-sparing surgery
versus radical nephroureterectomy for the treatment of UTUC
of the lower urinary tract. In this scenario, the real need of
randomized controlled trials is still debated, as elegantly
expressed by Briganti et al. for LND at the time of radical
prostatectomy for prostate cancer [43].
In conclusion, individualized tailoring of both indications and
extent of LND will be a key step forward in the treatment of
high-risk UTUC in order to maximize the oncological efficacy of
surgery while reducing its potential morbidity. While waiting
the results of future prospective trials, standardization of LND
templates according to laterality and location of the tumor and
accurate reporting of LND results within the published series is
needed to improve the quality of clinical research in this field.
Key issues
● According to the current evidence, lymph node dissection
(LND) has shown to improve staging, patient survival and
treatment of micro-metastases in patients with upper tract
urothelial carcinoma (UTUC). However, indications and
techniques of LND for UTUC are still debated and its ther-
apeutic benefit remains controversial.
● There is lack of standardization in the technique of LND among
surgeons and Institutionsworldwide,which is potentially driven
by the lack of specific Recommendations by the current inter-
national Guidelines.
● This is the first systematic review of the literature specifi-
cally designed to provide detailed data on the most com-
monly dissected surgical templates of LND for UTUC
according to both laterality and location of the tumour.
● Overall, 16 studies were selected for the analysis. An open
surgical approach for both radical nephroureterectomy and
LND was used in most studies, while a minimally invasive
approach (laparoscopic or robotic) only in selected series.
● In almost all studies, the choice to perform LND was left to the
surgeons’ judgment and/or was based on preoperative/intrao-
perative suspicion of lymph node metastases. Moreover, in
most studies the extent of LND was not standardized.
● For right-sided tumors of the renal pelvis, upper third and
middle third of the ureter, the LND template included in
most cases the renal hilar, paracaval, precaval and retro-
caval nodes, while for left-sided tumors the renal hilar, para-
aortic and preaortic nodes.
● For tumors of the lower ureter, an ipsilateral extended
pelvic LND including the common, external, internal iliac
and obturatory nodes was performed in most series.
However, the paracaval (for right-sided tumors), paraaortic
(for left-sided tumors) or the presacral nodes were also
dissected in selected studies.
● The lack of a standardized template of LND according to
laterality and/or location of UTUC may hinder a proper inter-
pretation of the oncologic results of the available surgical
series and a meaningful comparison of different LND techni-
ques, leading to potentially inaccurate estimations of the
specific anatomical sites of lymphatic drainage for each ana-
tomical location of UTUC.
● Prospective high-quality studies are required to provide
insights on the therapeutic efficacy of LND for UTUC.
Thus, standardization of LND templates and thoughtful
reporting of LND results will be key in the design of future
clinical trials to define the proper templates for each tumor
location and to assess their oncological efficacy and surgical
morbidity.
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